Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) - Net Assets
Based on the latest financial reports, Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) has net assets worth CN¥11.39 Billion CNY (≈ $1.67 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.18 Billion ≈ $2.07 Billion USD) and total liabilities (CN¥2.79 Billion ≈ $407.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002603 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.39 Billion |
| % of Total Assets | 80.34% |
| Annual Growth Rate | 20.16% |
| 5-Year Change | 21.05% |
| 10-Year Change | 105.93% |
| Growth Volatility | 55.61 |
Shijiazhuang Yiling Pharmaceutical Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Shijiazhuang Yiling Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002603 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual net assets of Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025. For live valuation and market cap data, see Shijiazhuang Yiling Pharmaceutical Co Lt (002603) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥10.98 Billion ≈ $1.61 Billion |
+7.64% |
| 2024-12-31 | CN¥10.20 Billion ≈ $1.49 Billion |
-10.81% |
| 2023-12-31 | CN¥11.44 Billion ≈ $1.67 Billion |
+4.65% |
| 2022-12-31 | CN¥10.93 Billion ≈ $1.60 Billion |
+20.48% |
| 2021-12-31 | CN¥9.07 Billion ≈ $1.33 Billion |
+1.67% |
| 2020-12-31 | CN¥8.92 Billion ≈ $1.31 Billion |
+12.21% |
| 2019-12-31 | CN¥7.95 Billion ≈ $1.16 Billion |
+5.14% |
| 2018-12-31 | CN¥7.56 Billion ≈ $1.11 Billion |
+6.35% |
| 2017-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+33.36% |
| 2016-12-31 | CN¥5.33 Billion ≈ $780.36 Million |
+10.47% |
| 2015-12-31 | CN¥4.83 Billion ≈ $706.40 Million |
+9.30% |
| 2014-12-31 | CN¥4.42 Billion ≈ $646.31 Million |
+3.72% |
| 2013-12-31 | CN¥4.26 Billion ≈ $623.13 Million |
+10.75% |
| 2012-12-31 | CN¥3.84 Billion ≈ $562.64 Million |
+3.87% |
| 2011-12-31 | CN¥3.70 Billion ≈ $541.67 Million |
+239.28% |
| 2010-12-31 | CN¥1.09 Billion ≈ $159.65 Million |
+38.01% |
| 2009-12-31 | CN¥790.55 Million ≈ $115.68 Million |
+63.33% |
| 2008-12-31 | CN¥484.03 Million ≈ $70.83 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shijiazhuang Yiling Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2167.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.07 Billion | 55.20% |
| Other Components | CN¥4.92 Billion | 44.80% |
| Total Equity | CN¥10.99 Billion | 100.00% |
Shijiazhuang Yiling Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shijiazhuang Yiling Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Airoha Technology Corp
TW:6526
|
$3.67 Billion |
|
Otter Tail Corporation
NASDAQ:OTTR
|
$3.67 Billion |
|
Beijing Shougang Co Ltd
SHE:000959
|
$3.68 Billion |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
$3.68 Billion |
|
OSI Systems Inc
NASDAQ:OSIS
|
$3.67 Billion |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
$3.66 Billion |
|
Sime Darby Bhd
KLSE:4197
|
$3.66 Billion |
|
Huaxin Cement Co Ltd A
SHG:600801
|
$3.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shijiazhuang Yiling Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,223,487,732 to 10,989,102,712, a change of 765,614,980 (7.5%).
- Net income of 1,286,478,663 contributed positively to equity growth.
- Dividend payments of 501,211,613 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.29 Billion | +11.71% |
| Dividends Paid | CN¥501.21 Million | -4.56% |
| Other Changes | CN¥-19.65 Million | -0.18% |
| Total Change | CN¥- | 7.49% |
Book Value vs Market Value Analysis
This analysis compares Shijiazhuang Yiling Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 37.48x to 2.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.40 | CN¥15.02 | x |
| 2009-12-31 | CN¥0.66 | CN¥15.02 | x |
| 2010-12-31 | CN¥0.89 | CN¥15.02 | x |
| 2011-12-31 | CN¥2.62 | CN¥15.02 | x |
| 2012-12-31 | CN¥2.51 | CN¥15.02 | x |
| 2013-12-31 | CN¥2.74 | CN¥15.02 | x |
| 2014-12-31 | CN¥2.85 | CN¥15.02 | x |
| 2015-12-31 | CN¥3.04 | CN¥15.02 | x |
| 2016-12-31 | CN¥3.35 | CN¥15.02 | x |
| 2017-12-31 | CN¥4.23 | CN¥15.02 | x |
| 2018-12-31 | CN¥4.51 | CN¥15.02 | x |
| 2019-12-31 | CN¥4.76 | CN¥15.02 | x |
| 2020-12-31 | CN¥5.34 | CN¥15.02 | x |
| 2021-12-31 | CN¥5.43 | CN¥15.02 | x |
| 2022-12-31 | CN¥6.54 | CN¥15.02 | x |
| 2023-12-31 | CN¥6.85 | CN¥15.02 | x |
| 2024-12-31 | CN¥6.12 | CN¥15.02 | x |
| 2025-12-31 | CN¥6.58 | CN¥15.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shijiazhuang Yiling Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.71%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.43%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.24x
- Recent ROE (11.71%) is below the historical average (12.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 25.36% | 13.01% | 1.13x | 1.73x | CN¥73.97 Million |
| 2009 | 37.73% | 18.21% | 1.08x | 1.92x | CN¥218.41 Million |
| 2010 | 28.92% | 19.13% | 0.93x | 1.62x | CN¥206.46 Million |
| 2011 | 12.27% | 23.25% | 0.46x | 1.14x | CN¥83.91 Million |
| 2012 | 4.83% | 11.27% | 0.40x | 1.08x | CN¥-198.69 Million |
| 2013 | 5.74% | 9.81% | 0.53x | 1.09x | CN¥-181.54 Million |
| 2014 | 8.03% | 12.14% | 0.57x | 1.15x | CN¥-87.18 Million |
| 2015 | 8.94% | 13.52% | 0.56x | 1.19x | CN¥-51.07 Million |
| 2016 | 10.01% | 13.84% | 0.62x | 1.18x | CN¥480.69K |
| 2017 | 7.60% | 13.25% | 0.52x | 1.11x | CN¥-170.31 Million |
| 2018 | 7.93% | 12.45% | 0.56x | 1.13x | CN¥-156.89 Million |
| 2019 | 7.63% | 10.41% | 0.64x | 1.14x | CN¥-187.94 Million |
| 2020 | 13.66% | 13.88% | 0.76x | 1.29x | CN¥326.81 Million |
| 2021 | 14.82% | 13.28% | 0.78x | 1.42x | CN¥436.94 Million |
| 2022 | 21.61% | 18.85% | 0.77x | 1.49x | CN¥1.27 Billion |
| 2023 | 11.81% | 13.11% | 0.61x | 1.48x | CN¥207.41 Million |
| 2024 | -7.09% | -11.12% | 0.49x | 1.30x | CN¥-1.75 Billion |
| 2025 | 11.71% | 16.43% | 0.57x | 1.24x | CN¥187.57 Million |
Industry Comparison
This section compares Shijiazhuang Yiling Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) | CN¥11.39 Billion | 25.36% | 0.24x | $3.67 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and pers… Read more